![]() |
Name |
phragamide B
|
Molecular Formula | C9H15NO3 | |
IUPAC Name* |
2-methyl-N-(3-oxobutanoyl)butanamide
|
|
SMILES |
CCC(C)C(=O)NC(=O)CC(C)=O
|
|
InChI |
InChI=1S/C9H15NO3/c1-4-6(2)9(13)10-8(12)5-7(3)11/h6H,4-5H2,1-3H3,(H,10,12,13)
|
|
InChIKey |
HSGMGFMNWAZIDN-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 185.22 | ALogp: | 0.7 |
HBD: | 1 | HBA: | 3 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 63.2 | Aromatic Rings: | 0 |
Heavy Atoms: | 13 | QED Weighted: | 0.666 |
Caco-2 Permeability: | -4.477 | MDCK Permeability: | 0.00003310 |
Pgp-inhibitor: | 0.061 | Pgp-substrate: | 0.258 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.006 |
30% Bioavailability (F30%): | 0.005 |
Blood-Brain-Barrier Penetration (BBB): | 0.998 | Plasma Protein Binding (PPB): | 20.21% |
Volume Distribution (VD): | 0.504 | Fu: | 76.76% |
CYP1A2-inhibitor: | 0.027 | CYP1A2-substrate: | 0.511 |
CYP2C19-inhibitor: | 0.076 | CYP2C19-substrate: | 0.731 |
CYP2C9-inhibitor: | 0.02 | CYP2C9-substrate: | 0.268 |
CYP2D6-inhibitor: | 0.006 | CYP2D6-substrate: | 0.165 |
CYP3A4-inhibitor: | 0.017 | CYP3A4-substrate: | 0.486 |
Clearance (CL): | 7.878 | Half-life (T1/2): | 0.888 |
hERG Blockers: | 0.01 | Human Hepatotoxicity (H-HT): | 0.062 |
Drug-inuced Liver Injury (DILI): | 0.132 | AMES Toxicity: | 0.025 |
Rat Oral Acute Toxicity: | 0.06 | Maximum Recommended Daily Dose: | 0.023 |
Skin Sensitization: | 0.806 | Carcinogencity: | 0.015 |
Eye Corrosion: | 0.087 | Eye Irritation: | 0.606 |
Respiratory Toxicity: | 0.223 |